NATCO Pharma Limited NATCOPHARM NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.natcopharma.co.in

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Market & Price

Market Cap

₹18,195.77 Cr

Current Price

₹1,015.90

High / Low (52W)

₹1,206.00 / ₹790.18

Beta

Valuation

Stock P/E

12.82

Industry PE

37.60

Forward P/E

22.35

PEG Ratio

Book Value

₹482.88

Price to Book

2.10

P/S

4.16

EV/EBITDA

9.68

Dividend Yield

0.64%

Profitability & Returns

ROCE

16.26%

ROE

16.85%

ROA

9.69%

Profit Margin

32.42%

Op Margin

18.97%

EPS (Latest Qtr)

₹14.96

EPS (TTM)

₹79.24

Balance Sheet & Liquidity

Debt/Equity

0.08

Quick Ratio

1.79

Current Ratio

3.01

Debt

₹713.90 Cr

Total Assets

₹11,073.70 Cr

Current Assets

₹5,052.30 Cr

Working Capital

₹3,371.40 Cr

Ownership

Promoter Holding

51.04%

Chg in Prom Hold

FII / Inst Holding

12.49%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹16,777.29 Cr

Total Revenue (TTM)

₹4,375.90 Cr

EBITDA

₹1,734.10 Cr

Free Cash Flow

₹1,006.65 Cr

Operating Cash Flow

₹1,768.30 Cr

Shares Outstanding

₹17.91 Cr

Gross Margin

97.78%

Payout Ratio

6.31%

Growth (CAGR)

Revenue 5Y

14.78%

Profit 5Y

25.64%

Revenue (YoY)

-33.20%

Earnings (YoY)

-34.10%

PROS

Excellent profit margin of 32.4%.
Compounding revenue at 14.8% over 5 years.
Profit CAGR of 25.6% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	NATCOPHARM NATCO Pharma Limited NIFTY_SMALLNSEPHARMA	1,015.90	12.82	₹18,195.77 Cr	0.64%	16.26%	16.85%	14.78%	25.64%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	474.80 Cr	1,221.00 Cr	1,328.90 Cr	1,363.00 Cr	647.30 Cr	739.10 Cr
Cost of Revenue	-	82.80 Cr	249.20 Cr	233.00 Cr	169.70 Cr	133.10 Cr	154.70 Cr
Gross Profit	-	392.00 Cr	971.80 Cr	1,095.90 Cr	1,193.30 Cr	514.20 Cr	584.40 Cr
Operating Expenses	-	400.20 Cr	522.00 Cr	582.50 Cr	666.50 Cr	401.70 Cr	507.20 Cr
Operating Income	-	-8.20 Cr	449.80 Cr	513.40 Cr	526.80 Cr	112.50 Cr	77.20 Cr
EBITDA	-	215.10 Cr	614.40 Cr	632.70 Cr	679.20 Cr	216.80 Cr	205.40 Cr
Interest Expense	-	4.40 Cr	10.20 Cr	3.20 Cr	13.10 Cr	9.50 Cr	10.90 Cr
Pretax Income	-	163.70 Cr	505.90 Cr	571.90 Cr	613.70 Cr	161.10 Cr	144.10 Cr
Tax Provision	-	31.30 Cr	99.90 Cr	91.60 Cr	95.80 Cr	20.70 Cr	-89.20 Cr
Net Income	-	133.00 Cr	406.60 Cr	480.70 Cr	518.40 Cr	151.50 Cr	267.90 Cr
Diluted EPS	37.81	7.43	22.70	26.84	28.94	8.46	14.96

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	2,696.90 Cr	3,978.80 Cr	4,429.50 Cr	4,078.30 Cr
Cost of Revenue	-	745.50 Cr	862.50 Cr	689.80 Cr	690.50 Cr
Gross Profit	-	1,951.40 Cr	3,116.30 Cr	3,739.70 Cr	3,387.80 Cr
Operating Expenses	-	1,161.30 Cr	1,539.50 Cr	1,778.90 Cr	2,157.90 Cr
Operating Income	-	790.10 Cr	1,576.80 Cr	1,960.80 Cr	1,229.90 Cr
EBITDA	-	1,035.20 Cr	1,872.30 Cr	2,550.50 Cr	1,734.10 Cr
Interest Expense	-	9.50 Cr	12.00 Cr	23.90 Cr	36.70 Cr
Pretax Income	-	861.90 Cr	1,673.50 Cr	2,291.40 Cr	1,490.80 Cr
Tax Provision	-	146.60 Cr	285.20 Cr	408.00 Cr	118.90 Cr
Net Income	-	715.30 Cr	1,388.30 Cr	1,885.40 Cr	1,418.50 Cr
Diluted EPS	9.32	39.18	77.34	105.26	-

Compounded Sales Growth

5 Years:	14.78%
1 Year:	-33.20%

Compounded Profit Growth

5 Years:	25.64%
1 Year:	-34.10%

Stock Price Performance

1 Year:	+14.33%
6 Months:	+22.02%
3 Months:	+7.52%
1 Month:	-7.29%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	5,657.40 Cr	6,906.30 Cr	8,630.80 Cr	11,073.70 Cr
Current Assets	-	3,000.30 Cr	4,023.50 Cr	5,270.00 Cr	5,052.30 Cr
Cash & Equivalents	-	131.90 Cr	70.40 Cr	120.00 Cr	198.90 Cr
Inventory	-	742.90 Cr	700.50 Cr	765.80 Cr	908.50 Cr
Receivables	-	856.10 Cr	1,188.90 Cr	1,246.60 Cr	881.20 Cr
Total Liabilities	-	783.60 Cr	1,053.20 Cr	1,018.50 Cr	1,852.60 Cr
Current Liabilities	-	683.10 Cr	972.80 Cr	943.50 Cr	1,680.90 Cr
Long Term Debt	-	-	-	-	100.00 Cr
Total Debt	-	176.10 Cr	371.20 Cr	279.40 Cr	713.90 Cr
Total Equity	-	4,873.80 Cr	5,853.10 Cr	7,607.00 Cr	9,221.10 Cr
Shares Outstanding	-	18.26 Cr	17.91 Cr	17.91 Cr	17.91 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	849.10 Cr	1,211.60 Cr	1,696.80 Cr	1,768.30 Cr
Investing Cash Flow	-	-477.10 Cr	-1,032.70 Cr	-1,414.50 Cr	-2,081.70 Cr
Financing Cash Flow	-	-363.00 Cr	-246.90 Cr	-210.70 Cr	297.50 Cr
Capital Expenditure	-	-205.60 Cr	-358.70 Cr	-511.60 Cr	-391.10 Cr
Free Cash Flow	-	643.50 Cr	852.90 Cr	1,185.20 Cr	1,377.20 Cr
Net Change in Cash	-	9.00 Cr	-68.00 Cr	71.60 Cr	-15.90 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	72.4%	78.3%	84.4%	83.1%
Operating Margin %	-	29.3%	39.6%	44.3%	30.2%
Net Margin %	-	26.5%	34.9%	42.6%	34.8%
ROE %	-	14.7%	23.7%	24.8%	15.4%
ROCE %	-	15.9%	26.6%	25.5%	13.1%

Shareholding Pattern

Insiders

51.04%

Institutions

12.49%

Public Float

25.52%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NATCOPHARM

No recent headlines available.

NATCOPHARM · Healthcare